Dimerization of G-protein-coupled receptors

Journal of Medicinal Chemistry

Volumn 44, Issue 26, 2001, Pages 4595-4614

  Dean, M K ^a   Higgs, C ^a   Smith, R E ^a   Bywater, R P ^b   Snell, C R ^c   Scott, P D ^a   Upton, G J G ^a   Howe, T J ^d   Reynolds, C A ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c Novatis Inst for Medical Sciences   (United Kingdom)

^d NOVARTIS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; G PROTEIN COUPLED RECEPTOR;

ARTICLE; CONFORMATIONAL TRANSITION; DIMERIZATION; MOLECULAR EVOLUTION; OLIGOMERIZATION; PREDICTION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; SYSTEM ANALYSIS;

AMINO ACID SEQUENCE; CONSENSUS SEQUENCE; DIMERIZATION; GTP-BINDING PROTEINS; MODELS, MOLECULAR; MONTE CARLO METHOD; MUTATION; RECEPTORS, CELL SURFACE;

EID: 0035924184     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010290+     Document Type: Article

References (187)

1. Gonadotropin-releasing hormone stimulation of luteinizing hormone release: A ligand-receptor-effector model
2. Agonist-induced increase in apparent beta-adrenergic receptor size
3. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors
4. Narcotic antagonistic potency of bivalent ligands which contain β-naltrexamine. Evidence for bridging between proximal recognition sites
5. Monoclonal antibodies to purified muscarinic receptor display agonist-like activity
6. Oligomeric structure of muscarinic receptors is shown by photoaffinity labeling: Subunit assembly may explain
7. Potency enhancement of a GnRH agonist: GnRH-receptor microaggregation stimulates gonadotropin release
8. Conversion of a gonadotropin-releasing hormone antagonist to an agonist
9. Gonadotropin releasing hormone activation is mediated by dimerization of occupied receptors
10. Immunological identification of A1 adenosine receptors in brain cortex
11. A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation
12. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET)
13. 2-adrenergic receptor that exploits the domain structure of G-protein-coupled receptors
14. Domain swapping in G-protein coupled receptor dimers
15. Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. Reconstitution of the binding site by co-expression of two deficient mutants
16. Dopamine D2 receptor dimers and receptor-blocking peptides
17. Dopamine D2 receptor dimers in human and rat brain
18. Identification and molecular characterization of m3 muscarinic receptor dimers
19. Dimerization of the delta opioid receptor: Implication for a role in receptor internalization
20. G-protein-coupled receptor heterodimerization modulates receptor function
21. Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells
22. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor
23. Metabotropic glutamate receptor 5 is a disulfide-linked dimer
24. B heterodimer: Interacting protein partners as revealed by yeast two hybrid studies
25. GABA(B)-receptor subtypes assemble into functional heteromeric complexes
26. The heteromeric GABA-B receptor recognizes G-protein alpha subunit C-termini
27. GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2
28. Molecular tinkering of G protein-coupled receptors: An evolutionary success
29. Dimerization of cell surface receptors in signal transduction
30. Our genome unveiled
31. Correlated mutations contain information about protein-protein interaction
32. Protein-sequence alignments - A strategy for the hierarchical analysis of residue conservation
33. Identification of functional surfaces of the zinc binding domains of intracellular receptors
34. The relation between the divergence of sequence and structure in proteins
35. Prediction of protein secondary structure and active sites using the alignment of homologous sequences
36. Structural basis of G protein-coupled receptor function
37. Structure and function of G protein-coupled receptors
38. Molecular basis of receptor/G-protein-coupling selectivity
39. Crystal structure of rhodopsin: A G protein-coupled receptor
40. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein coupled receptors (GPCRs)
41. The 2.0 A crystal structure of a heterotrimeric G protein
42. Structure of RGS4 bound to AlF4-activated G(i alpha1): Stabilization of the transition state for GTP hydrolysis
43. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS
44. Evolutionary trace analysis of TGF-beta and related growth factors: Implications for site-directed mutagenesis
45. Prediction and confirmation of a site critical for effector regulation of RGS domain activity
46. A regulator of G protein signaling interaction surface linked to effector specificity
47. Analysis of heregulin symmetry by weighted evolutionary tracing
48. Evolutionary trace analysis of the Kunitz/BPTI family of proteins: Functional divergence may have been based on conformational adjustment
49. Identification of class-determining residues in G protein-coupled receptors by sequence analysis
50. The interaction of class B G protein-coupled receptors with their hormones
51. 2-adrenergic receptor from the evolutionary trace method
52. Evolutionarily conserved Galphabetagamma binding surfaces support a model of the G protein-receptor complex
53. Mapping of contact sites in complex formation between transducin and light-activated rhodopsin by covalent crosslinking: Use of a photoactivatable reagent
54. Mapping of contact sites in complex formation between light-activated rhodopsin and transducin by covalent crosslinking: Use of a chemically preactivated reagent
55. An evolutionary trace method defines binding surfaces common to protein families
56. GPCRDB: An information system for G protein-coupled receptors
57. Structure of the integral membrane domain of the GLP1 receptor
58. PHYLIP-Phylogeny inference package (version 3.2)
59. Diffusion-controlled enzymatic reactions
60. A graphics program for the analysis and display of molecular dynamics trajectories
61. Control of topology and mode of assembly of a polytopic membrane protein by positively charged residues
62. Evidence for adenosine/dopamine receptor interactions: Indications for heteromerization
63. Metabotropic Glutamate 1alpha and Adenosine A1 Receptors Assemble into Functionally Interacting Complexes
64. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration
65. Chemokine receptor
66. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity
67. Heterodimerization is required for the formation of a functional GABA(B) receptor
68. G protein-linked receptors: Pharmacological evidence for the formation of heterodimers
69. Muscarinic M3 receptor inactivation reveals a pertussis toxin-sensitive contractile response in the guinea pig colon: Evidence for M2/M3 receptor interactions
70. Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone and heterodimers when co-expressed
71. Subtypes of the somatostatin receptor assemble as functional
72. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
73. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment
74. Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product
75. The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor
76. Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors
77. Simulations on dimeric peptides: Evidence for domain swapping in G-protein-coupled receptors?
78. Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6
79. GABAB receptors make it to the top-as dimers
80. Influence of proline residues on protein conformation
81. Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors
82. Functional role of the third cytoplasmic loop in muscarinic receptor dimerization
83. Examining rhodopsin folding and assembly through expression of polypeptide fragments
84. Chimeric alpha 2-,beta 2-adrenergic receptors: Delineation of domains involved in effector coupling and ligand binding specificity
85. Plasma membrane localization and functional rescue of truncated forms of a G protein-coupled receptor
86. Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide
87. Functional and structural complexity of signal transduction via G-protein-coupled receptors
88. Split-receptors in the tachykinin neurokinin-1 system - Mutational analysis of intracellular loop 3
89. Dimerizationa and domain swapping in G-protein coupled receptors: A computational study
90. Effects of GABAB receptor subunit chimeras on receptor localisation and ligand binding
91. Construction of a high affinity zinc switch in the kappa-opioid receptor
92. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors
93. A low resolution model for the interaction of G proteins with G protein-coupled receptors
94. Site-directed mutagenesis of the rat m1 muscarinic acetylcholine receptor. Role of conserved cysteines in receptor function
95. The ligand binding site of the neurokinin 2 receptor. Site-directed mutagenesis and identification of neurokinin A binding residues in the human neurokinin 2 receptor
96. Identification of residues involved in ligand binding to the neurokinin-2 receptor
97. Mapping of the amino acids in membrane-embedded helices that interact with the retinal chromophore in bovine rhodopsin
98. A receptors
99. Correlated mutations and subtype specificity in the adrenergic receptor
100. Correlated mutations amongst the external residues of G-protein coupled receptors
101. Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors
102. Cardiac muscarinic receptors. Cooperativity as the basis for multiple states of affinity
103. Effects of adenyl nucleotides and carbachol on cooperative interactions among G proteins
104. Cardiac muscarinic receptors. Relationship between the G protein and multiple states of affinity
105. The helical domain of a G protein alpha subunit is a regulator of its effector
106. Separate GTP binding and GTPase activating domains of a G alpha subunit
107. Carboxyl terminal domain of Gs alpha specifies coupling of receptors to stimulation of adenylyl cyclase
108. An antibody directed against residues 100-119 within the alphahelical domain of Galpha(s) defines a novel contact site for beta-adrenergic receptors
109. Inhibitory effect of isoproterenol on NADPH-dependent H(2)O-(2) generation in human adipocyte plasma membranes is mediated by betagamma-subunits derived from G(s)
110. Palmitoylation is required for signaling functions and membrane attachment of Gq alpha and Gs alpha
111. Lipid modifications of trimeric G proteins
112. Interaction with Gbetagamma is required for membrane targeting and palmitoylation of Galpha(s) and Galpha(q)
113. Signal transfer from rhodopsin to the G-protein: Evidence for a two-site sequential fit mechanism
114. Oligomerization of opioid receptors with beta 2-adrenergic receptors: A role in trafficking and mitogen-activated protein kinase activation
115. A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization
116. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: Dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely
117. Direct demonstration of three different states of the pancreatic cholecystokinin receptor
118. Biochemical regulation of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini
119. Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini
120. Multiple affinity states of different cholecystokinin receptors
121. Structural implication for receptor oligomerization from functional reconstitution studies of mutant V2 vasopressin receptors
122. Three-dimensional domain swapping in p13suc1 occurs in the unfolded state and is controlled by conserved proline residues
123. Identification of a Gs activator region of the beta 2-adrenergic receptor that is autoregulated via protein kinase A-dependent phosphorylation
124. Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: A site-directed spin-labeling study
125. Three-dimensional structure of the cytoplasmic face of the G protein receptor rhodopsin
126. Structure of the G-protein-coupled receptor, rhodopsin: A domain approach
127. Solution structure of the sixth transmembrane helix of the G-protein-coupled receptor, rhodopsin(1)
128. Mechanism of insulin and IGF-I receptor activation and signal transduction specificity. Receptor dimer cross-linking, bell-shaped curves, and sustained versus transient signaling
129. A model of non-exclusive binding of agonist and antagonist on G-protein coupled receptors
130. Targeting the dimerization interface of HIV-1 protease: Inhibition with cross-linked interfacial peptides
131. The sequence of the human genome
132. A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of a1 and a3 adenosine receptor agonists
133. Oligomer formation by 3D domain swapping: A model for protein assembly and misassembly
134. 3D domain swapping: A mechanism for oligomer assembly
135. Domain swapping: Entangling alliances between proteins
136. Amino acids of the third transmembrane domain of the AT1A angiotensin II receptor are involved in the differential recognition of peptide and nonpeptide ligands
137. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms
138. Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors
139. Human P2Y1 receptor: Molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites
140. A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor
141. Role of aromatic transmembrane residues of the delta-opioid receptor in ligand recognition
142. Dopamine D1 receptor mutagenesis: Role of amino acids in agonist and antagonist binding
143. Both extracellular and transmembrane residues contribute to the species selectivity of the neurokinin-1 receptor antagonist WIN 51708
144. Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: Ergolines require an aromatic residue at position 340 for high affinity binding
145. Mutagenesis of 5HT2 serotonin receptors: What does an analysis of mutant receptors tell us?
146. Modulation by certain conserved aspartate residues of the allosteric interaction of gallamine at the m1 muscarinic receptor
147. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor
148. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan
149. Hydrophobic residues of the D2 dopamine receptor are important for binding and signal transduction
150. Mutagenesis and modeling of the neurotensin receptor NTR1. Identification of residues that are critical for binding SR 48692, a nonpeptide neurotensin antagonist
151. Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor
152. αq subunits
153. Molecular basis for the species selectivity of the substance P antagonist CP-96,345
154. Identification of critical determinants of alpha 1-adrenergic receptor subtype selective agonist binding
155. 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists
156. Differential roles of exoloop 1 of the human follicle-stimulating hormone receptor in hormone binding and receptor activation
157. Complete mutagenesis of the extracellular domain of interleukin-8 (IL-8) type A receptor identifies charged residues mediating IL-8 binding and signal transduction
158. Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants
159. Mutation of peptide binding site in transmembrane region of a G protein-coupled receptor accounts for endothelin receptor subtype selectivity
160. Molecular basis for the interaction of [Nle4,D-Phe7]melanocyte stimulating hormone with the human melanocortin-1 receptor
161. Ser-268 plays an important role in ligand binding of prostaglandin E2 receptor EP3alpha subtype
162. Evidence for alternate points of attachment for alpha-MSH and its stereoisomer [Nle4, D-Phe7]-alpha-MSH at the melano-cortin-1 receptor
163. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor
164. Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction
165. Probing the "message:address" sites for chemoattractant binding to the C5a receptor. Mutagenesis of hydrophilic and proline residues within the transmembrane segments
166. Functional role of proline and tryptophan residues highly conserved among G protein-coupled receptors studied by mutational analysis of the m3 muscarinic receptor
167. Mapping of the amino acids in membrane-embedded helices that interact with the retinal chromophore in bovine rhodopsin
168. Constitutive activation of the thyrotropin receptor by mutating CYS-636 in the sixth transmembrane segment
169. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease
170. Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor
171. Mutational analysis of neurokinin receptor function
172. Conformational compatibility as a basis of differential affinities of tachykinins for the neurokinin-1 receptor
173. Residues specifically involved in down-regulation but not internalization of the m1 muscarinic acetylcholine receptor
174. Alanine scanning mutagenesis of conserved arginine/lysine-arginine/lysine-X-X-arginine/lysine G protein-activating motifs on m1 muscarinic acetylcholine receptors
175. Identification of the site in the substance P (NK-1) receptor for modulation of peptide binding by sulfhydryl reagents
176. Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa
177. Dopamine D4 receptor variant in Africans, D4valine194glycine, is insensitive to dopamine and clozapine: Report of a homozygous individual
178. Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules
179. Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa. Clustering of functional classes along the polypeptide chain
180. Receptor and betagamma binding sites in the alpha subunit of the retinal G protein transducin